The Mechanistic Role of BRCA1-BARD1 DNA and RAD51 Binding in DNA Double-Strand Break Repair
Project Number1F30CA278370-01
Contact PI/Project LeaderJASPER, ANGELA MARY
Awardee OrganizationUNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Description
Abstract Text
ABSTRACT
Genomic instability is a hallmark of cancer, enabling the generation of mutations and gross chromosomal
rearrangements to drive neoplastic cell transformation and oncogenesis. A variety of conserved DNA repair
mechanisms eliminate DNA damage, and defects in these DNA repair pathways lead to genomic instability and
cancer. Homologous recombination (HR) is one such DNA repair pathway, which mediates the accurate repair
of highly toxic double-strand DNA breaks (DSBs) and damaged DNA replication forks. BRCA1 and its obligate
binding partner BARD1, both suppressors of breast, ovarian, and other cancers, fulfill multifaceted roles in HR.
Specifically, the BRCA1-BARD1 complex influences DSB repair pathway choice and enhances the efficiency of
several HR steps, including the nucleolytic processing of DNA lesions, the assembly of DSB repair nucleoprotein
complexes that harbor the recombinase RAD51, and DNA strand invasion. We posit that the DNA and RAD51
binding attributes of BRCA1-BARD1 are germane for the DSB repair and replication fork maintenance functions
of this tumor suppressor complex. To help fill major knowledge gaps, this fellowship proposal strives to delineate
RAD51 and DNA interaction interfaces in BRCA1-BARD1 and to elucidate the mechanistic roles of these
biochemical attributes in HR-mediated DNA repair and the protection of stressed and damaged DNA replication
forks. Our objectives will be accomplished through biochemical and cell-based studies under two specific aims.
The results of our endeavors will clarify the functional relevance of clinical mutations within BRCA1-BARD1
domains and create new avenues for the development of novel therapeutics to target tumors deficient in DNA
repair.
Public Health Relevance Statement
PROJECT NARRATIVE
The BRCA1-BARD1 protein complex acts to eliminate highly toxic DNA double-strand breaks, to ensure the
faithful propagation of our genetic blueprint, and to suppress cancer development. However, there is little
information regarding the intricate roles fulfilled by BRCA1-BARD1 in these processes, or how loss of specific
BRCA1-BARD1 functions leads to tumorigenesis. Elucidating the DNA and RAD51 interaction interfaces of
BRCA1-BARD1 and their function in DNA damage repair and DNA replication fork preservation will help
illuminate the functional consequence of cancer mutations in BRCA1-BARD1 and lay the foundation for
developing therapeutic strategies to target tumors deficient in DNA repair.
NIH Spending Category
CancerGenetics
Project Terms
BARD1 geneBRCA1 geneBindingBiochemicalBiochemistryBiologicalBreastCancer BiologyCause of DeathCellsCessation of lifeChromosomal RearrangementClinicalComplexDNADNA BindingDNA Binding DomainDNA DamageDNA Double Strand BreakDNA RepairDNA Repair GeneDNA Repair PathwayDNA Replication DamageDNA lesionDNA replication forkDefectDevelopmentDiseaseDouble Strand Break RepairEnsureExcisionExposure toFanconi's AnemiaFellowshipFilamentFoundationsFutureGenerationsGenesGeneticGenomeGenome StabilityGenomic InstabilityHereditary Breast and Ovarian Cancer SyndromeImpairmentInvadedKnowledgeLabelLaboratoriesLeadLocationMaintenanceMalignant NeoplasmsMapsMediatingMutationNeoplastic Cell TransformationNonhomologous DNA End JoiningNucleoproteinsOvarianPathway interactionsPhysiciansProcessProteinsRad51 recombinaseResearch PersonnelRoleScientistSingle-Stranded DNASister ChromatidSite-Directed MutagenesisStressSyndromeSystemTailTertiary Protein StructureTestingTherapeuticTrainingTumor Suppressor ProteinsWorkcareerclinically relevantdesignhomologous recombinationinsertion/deletion mutationmutantnovel therapeuticsp53-binding protein 1preservationpresynapticprotective pathwayprotein complexreconstitutionrepairedrestorationsynergismtherapeutic developmenttooltumortumorigenesis
No Sub Projects information available for 1F30CA278370-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F30CA278370-01
Patents
No Patents information available for 1F30CA278370-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F30CA278370-01
Clinical Studies
No Clinical Studies information available for 1F30CA278370-01
News and More
Related News Releases
No news release information available for 1F30CA278370-01
History
No Historical information available for 1F30CA278370-01
Similar Projects
No Similar Projects information available for 1F30CA278370-01